BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
The class of innovators in BioCentury’s 2022 Emerging Company Profiles reveals the emergence of protein stabilization as a counterpart to the already popular approach of targeted protein degradation. The companies also showcase the cutting edge of gene therapy delivery and CAR T cell engineering, and provide a view into the latest translational advances in neurology.
The collection, which comprises 96 private companies, focuses on novel platform technologies and therapies that could be first in class or best in class. Most of the companies emerged from stealth or raised their first venture rounds in the past five years. The class represents a curated group of companies with compelling science, rather than a comprehensive collection of start-ups...